Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system disorders, announced multiple presentations on their treatments AXS-12 and solriamfetol at the 39th annual meeting of the Associated Professional Sleep Societies (APSS), SLEEP 2025, held from June 8-11, 2025, in Seattle, Washington. The presentations included results from clinical trials and real-world studies. Notably, the results of the Phase 3 SYMPHONY trial and the ENCORE trial for AXS-12 in narcolepsy were presented, highlighting its impact on symptom severity and functional impairment. Additionally, solriamfetol was discussed in the context of excessive daytime sleepiness in patients with obstructive sleep apnea. The presentations were scheduled for June 11, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.